Rocket Pharmaceuticals (RCKT) Tops Q1 EPS by 3c

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q1 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Citi raises Salesforce price target to $204, keeps Neutral rating
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform